Cargando…

A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas

Serological tests have been widely used for detecting human T-cell lymphotropic virus type 1/2 (HTLV-1/2) antibodies in the endemic areas, but their performance in low-risk populations is rarely reported. The aim of this study was to evaluate the performance of four HTLV-1/2 screening assays and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Huimin, Chang, Le, Yan, Ying, Jiang, Xinyi, Sun, Huizhen, Guo, Fei, Wang, Lunan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283491/
https://www.ncbi.nlm.nih.gov/pubmed/32582093
http://dx.doi.org/10.3389/fmicb.2020.01151
_version_ 1783544311054336000
author Ji, Huimin
Chang, Le
Yan, Ying
Jiang, Xinyi
Sun, Huizhen
Guo, Fei
Wang, Lunan
author_facet Ji, Huimin
Chang, Le
Yan, Ying
Jiang, Xinyi
Sun, Huizhen
Guo, Fei
Wang, Lunan
author_sort Ji, Huimin
collection PubMed
description Serological tests have been widely used for detecting human T-cell lymphotropic virus type 1/2 (HTLV-1/2) antibodies in the endemic areas, but their performance in low-risk populations is rarely reported. The aim of this study was to evaluate the performance of four HTLV-1/2 screening assays and to discuss a strategy for diagnosis of HTLV-1/2 infection in a non-endemic area. At the present study, 1546 specimens repeatedly reactive (RR) by one screening ELISA were collected from blood centers/banks from January 2016 to April 2019. Avioq-ELISA, Murex-ELISA, Roche-ECLIA and Fujirebio-CLIA were independently performed on each plasma sample and compared to WB and LIA confirmatory tests. Positive or indeterminate specimens with blood available were quantified by qPCR. The results showed that 48 samples were finally confirmed as HTLV-1 positive, 13 were HTLV positive, 151 were indeterminate, and 387 were negative. All the WB-positive samples were also LIA-positive. Roche-ECLIA showed the highest sensitivity that was able to detect 91.8% positives and combined with the Murex-ELISA would significantly increase the positive detection rate (98.4%). In addition, LIA yield more indeterminate and HTLV-untyped results than WB (152 vs. 27), but was able to resolve infection status of some individuals with an indeterminate WB. Besides, 3 WB indeterminate and 1 LIA-untyped samples were confirmed as HTLV-1 positive by qPCR. Based on these findings, we put forward a proper test strategy for HTLV-1/2 diagnosis in low-prevalence areas. If possible, the Roche-ECLIA with the highest sensitivity is suggested as a second screening assay in primary labs. If not, all RR specimens are recommended to be firstly retested by Roche-ECLIA and Murex-ELISA in the reference lab. Secondly, samples reactive to any one of the two tests were quantified by qPCR, and then the NAT-negatives were furtherly submitted to LIA for confirmation. Thereby, the cost can be reduced and the diagnostic accuracy would be improved.
format Online
Article
Text
id pubmed-7283491
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72834912020-06-23 A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas Ji, Huimin Chang, Le Yan, Ying Jiang, Xinyi Sun, Huizhen Guo, Fei Wang, Lunan Front Microbiol Microbiology Serological tests have been widely used for detecting human T-cell lymphotropic virus type 1/2 (HTLV-1/2) antibodies in the endemic areas, but their performance in low-risk populations is rarely reported. The aim of this study was to evaluate the performance of four HTLV-1/2 screening assays and to discuss a strategy for diagnosis of HTLV-1/2 infection in a non-endemic area. At the present study, 1546 specimens repeatedly reactive (RR) by one screening ELISA were collected from blood centers/banks from January 2016 to April 2019. Avioq-ELISA, Murex-ELISA, Roche-ECLIA and Fujirebio-CLIA were independently performed on each plasma sample and compared to WB and LIA confirmatory tests. Positive or indeterminate specimens with blood available were quantified by qPCR. The results showed that 48 samples were finally confirmed as HTLV-1 positive, 13 were HTLV positive, 151 were indeterminate, and 387 were negative. All the WB-positive samples were also LIA-positive. Roche-ECLIA showed the highest sensitivity that was able to detect 91.8% positives and combined with the Murex-ELISA would significantly increase the positive detection rate (98.4%). In addition, LIA yield more indeterminate and HTLV-untyped results than WB (152 vs. 27), but was able to resolve infection status of some individuals with an indeterminate WB. Besides, 3 WB indeterminate and 1 LIA-untyped samples were confirmed as HTLV-1 positive by qPCR. Based on these findings, we put forward a proper test strategy for HTLV-1/2 diagnosis in low-prevalence areas. If possible, the Roche-ECLIA with the highest sensitivity is suggested as a second screening assay in primary labs. If not, all RR specimens are recommended to be firstly retested by Roche-ECLIA and Murex-ELISA in the reference lab. Secondly, samples reactive to any one of the two tests were quantified by qPCR, and then the NAT-negatives were furtherly submitted to LIA for confirmation. Thereby, the cost can be reduced and the diagnostic accuracy would be improved. Frontiers Media S.A. 2020-06-03 /pmc/articles/PMC7283491/ /pubmed/32582093 http://dx.doi.org/10.3389/fmicb.2020.01151 Text en Copyright © 2020 Ji, Chang, Yan, Jiang, Sun, Guo and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Ji, Huimin
Chang, Le
Yan, Ying
Jiang, Xinyi
Sun, Huizhen
Guo, Fei
Wang, Lunan
A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
title A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
title_full A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
title_fullStr A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
title_full_unstemmed A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
title_short A Strategy for Screening and Confirmation of HTLV-1/2 Infections in Low-Endemic Areas
title_sort strategy for screening and confirmation of htlv-1/2 infections in low-endemic areas
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283491/
https://www.ncbi.nlm.nih.gov/pubmed/32582093
http://dx.doi.org/10.3389/fmicb.2020.01151
work_keys_str_mv AT jihuimin astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT changle astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT yanying astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT jiangxinyi astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT sunhuizhen astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT guofei astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT wanglunan astrategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT jihuimin strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT changle strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT yanying strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT jiangxinyi strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT sunhuizhen strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT guofei strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas
AT wanglunan strategyforscreeningandconfirmationofhtlv12infectionsinlowendemicareas